AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1296148
Drug: carbocalcitonin nasal
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbocalcitonin nasal spray 80 UMRC/day/1 month and 80 UMRC/alternating days/2 months followed by 1 month of wash-out for 11 months
Trial: 1296148
Drug: ipriflavone x
RxNorm normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipriflavone x os 600 mg/day/3 months followed by 1 month of wash-out for 3 times
Trial: 26654691
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (Phase 1)
Trial: 24611967
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg t.i.d.) and carnitine-orotate complex (300 mg t.i.d.)
Trial: 24611967
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg t.i.d.)
Trial: 20001318
Drug: Active LLLT
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active LLLT with nimesulide 200 mg/day
Trial: 20001318
Drug: Placebo LLLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LLLT with nimesulide 200 mg/day
Trial: 2354092
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate 500 micrograms
Trial: 2354092
Drug: Morphine-6-glucuronide (M6G)
RxNorm normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-glucuronide (M6G) 500 micrograms
Trial: 2354092
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate
Trial: 25744158
Drug: Erythritol 20
RxNorm normalized name: pentaerythritol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol 20 g
Trial: 25744158
Drug: Erythritol 25
RxNorm normalized name: Erythritol
DrugBank: Erythritol (DB04481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol 25 g
Trial: 25744158
Drug: Erythritol 15
RxNorm normalized name: Erythritol
DrugBank: Erythritol (DB04481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol 15 g
Trial: 25744158
Drug: Erythritol 5
RxNorm normalized name: pentaerythritol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol 5 g
Trial: 21370769
Drug: Additional manual
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional manual therapy techniques to the temporomandibular region
Trial: 21370769
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group (manual therapy for the cervical region)
Trial: 19227169
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (ropivacaine 0.18% and fentanyl 45.5 microg x ml(‐1) at 2 ml x hr(‐1))
Trial: 19227169
Drug: Continuous hypodermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hypodermic infusion (morphine 0.04 mg x kg(‐1) x ml(‐1) at 0.5 ml x hr(‐1); bolus: 0.5 ml x hr(‐1))
Trial: 10868317
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Celecoxib
Trial: 29222135
Drug: Ambulatory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory treatment (OP)
Trial: 24694475
Drug: Steroids alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids alone (methylprednisolone, MP group; n=25)
Trial: 24694475
Drug: Steroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids plus cyclosporine A (combination group; n=23)
Trial: 21600712
Drug: Gauze packing
RxNorm normalized name: Nu-Gauze Packing Strip Selvage Edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gauze packing (Group G)
Trial: 8786250
Drug: PABA 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PABA 1.5 g orally every 6 hours for 5 days with intravenous procainamide 750 mg
Trial: 8786250
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide alone
Trial: 37493
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 x 1 mg)
Trial: 37493
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 x 2 mg)
Trial: 37493
Drug: Clemastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine (2 x 1 mg)
Trial: 37493
Drug: Ketotifen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (3 and 14 days after treatment)
Trial: 28921654
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (0.0 and 0.65 g/kg)
Trial: 19028832
Drug: Cyclic methylprednisolone
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months
Trial: 2189989
Drug: Naftifine cream
RxNorm normalized name: naftifine Topical Cream
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine cream 1%
Trial: 7000475
Drug: Cimetidine (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.6 g/day)
Trial: 31405646
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (100 μg or 4000 IU daily)
Trial: 7537170
Drug: Astemizole-D (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole-D (10 mg astemizole plus 240 mg pseudoephedrine) once daily
Trial: 7537170
Drug: Beclomethasone nasal
RxNorm normalized name: beclomethasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone nasal spray (0.05 mg/ml) two puffs/nostril twice daily
Trial: 31913907
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) for stage I NSCLC
Trial: 19761652
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg Zn2+/day)
Trial: 16720138
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefazolin (group A)
Trial: 16720138
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL isotonic sodium chloride solution (group B; control)
Trial: 11760033
Drug: 0.1% dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dexamethasone phosphate eye gel
Trial: 15627154
Drug: 1% prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prednisolone acetate eye suspension
Trial: 9159563
Drug: Frusemide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide administered as a slow-rate infusion
Trial: 9159563
Drug: Frusemide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide administered in combination with 2 g of probenecid
Trial: 9159563
Drug: Frusemide bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide bolus dose
Trial: 3683453
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of mixed gangliosides (Cronassial)
Trial: 31838596
Drug: Probiotic milk
RxNorm normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic milk (Lactobacillus paracasei SD1) daily (group II)
Trial: 28034704
Drug: Oral antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidants (2 g ascorbate, 1.2 g N-acetylcysteine, 600 mg lipoic acid, 30 mg beta carotene)
Trial: 25421868
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of naftopidil
Trial: 25421868
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of naftopidil
Trial: 24024769
Drug: Chromium nicotinate
RxNorm normalized name: Chromium Nicotinate
DrugBank: Chromium nicotinate (DB14529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium nicotinate 50 μg (NC50)
Trial: 24024769
Drug: Chromium nicotinate
RxNorm normalized name: Chromium Nicotinate
DrugBank: Chromium nicotinate (DB14529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium nicotinate 200 μg (NC200)
Trial: 18321515
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment before infertility treatment
Trial: 14751919
Drug: Conservative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatments for prostate cancer
Trial: 11397883
Drug: Estring treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estring treatment (7.5 microg per 24 h)
Trial: 8503751
Drug: Early, intensive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early, intensive, gait‐focused physical therapy
Trial: 8503751
Drug: Early, intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early, intensive and conventional therapy
Trial: 8503751
Drug: Routine conventional
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine conventional therapy that started later and was not intense
Trial: 29136228
Drug: Opioid prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid prescription
Trial: 28750549
Drug: Error augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error augmentation
Trial: 20833862
Drug: Multidisciplinary falls
RxNorm normalized name: Halls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary falls prevention programme (including physiotherapy, occupational therapy, nurse, medical review, referral to specialists)
Trial: 12760507
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment only (scaling and root planing)
Trial: 11689389
Drug: Paricalcitol dosing
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol dosing based on baseline intact parathyroid hormone (iPTH; PTH/80) level
Trial: 11689389
Drug: Paricalcitol dosing
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol dosing based on patient body weight (0.04 microgram/kg)
Trial: 9393221
Drug: Antiretroviral combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral combination therapies (1991-1996)
Trial: 8180867
Drug: 100% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Trial: 8180867
Drug: 75% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Trial: 8180867
Drug: 65% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Trial: 8180867
Drug: 50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Trial: 8180867
Drug: 30% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Trial: 3286517
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d. for UTI (22 cases)
Trial: 3286517
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg b.i.d. for UTI (20 cases)
Trial: 3286517
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg s.i.d. for UTI (20 cases)
Trial: 3286517
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d. for RTI (10 cases)
Trial: 3286517
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg b.i.d. for RTI (20 cases)
Trial: 24418877
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g daily whole bean soy consumption for 18 months
Trial: 14768515
Drug: Fentanyl-isoflurane anesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fentanyl-isoflurane anesthesia (infusion of fentanyl at 3 micrograms/kg/h and maintained with isoflurane up to 0.6% end-tidal concentration)
Trial: 8676624
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg riluzole daily
Trial: 8676624
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg riluzole daily
Trial: 8676624
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg riluzole daily
Trial: 30770426
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) (±10,000 lux)
Trial: 28474556
Drug: Ferritin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin levels up to about 80 ng/mL
Trial: 28474556
Drug: Ferritin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin levels up to about 100 ng/mL
Trial: 28474556
Drug: Ferritin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin levels over 100 ng/mL
Trial: 28474556
Drug: Modified normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified normal ranges for ferritin from about 15 ng/mL up to about 80-100 ng/mL
Trial: 23614539
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - 1.0 g loading dose followed by another 1.0 g dose 3 hours later
Trial: 21904221
Drug: Acute normovolemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute normovolemic hemodilution (HG) - 1000 mL of blood drawn and replaced with HES 130/0.4 (6%, Voluven) colloid.
Trial: 18372722
Drug: Scopolamine (SCOP)
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine (SCOP) in combination with dextroamphetamine (DEX)
Trial: 9138853
Drug: Nadolol (hydrophilic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (hydrophilic beta-blocker)
Trial: 9138853
Drug: Metoprolol (lipophilic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (lipophilic beta-blocker)
Trial: 7831697
Drug: Department of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Department of Medicine
Trial: 2194380
Drug: Monovalent CR
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent CR influenza virus vaccine (type A H3N2, H1N1 and type B)
Trial: 2194380
Drug: Bivalent CR
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent CR influenza virus vaccine (type A H3N2 and H1N1)
Trial: 2194380
Drug: CR influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR influenza virus vaccine
Trial: 382156
Drug: Intravenous domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous domperidone (20 mg initially, followed by maintenance doses of 10 mg at 6 hourly intervals)
Trial: 31475465
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil solution applied every 12 hours for 30 days
Trial: 31475465
Drug: Hyperoxygenated fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperoxygenated fatty acid compound applied every 12 hours for 30 days
Trial: 29254111
Drug: FES therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES therapy plus conventional rehabilitation program
Trial: 23392087
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions (OHI) annually (Control group)
Trial: 23392087
Drug: OHI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHI and SDF application annually, plus oral health education (OHE) programme every 6 months
Trial: 15101070
Drug: Crisis intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisis intervention model (additional therapy visits if needed)
Trial: 15101070
Drug: Follow-up only
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up only (no additional therapy visits)
Trial: 3553495
Drug: Beta-blocker (oxprenolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (oxprenolol)
Trial: 3553495
Drug: Calcium-entry blocker
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-entry blocker (nitrendipine)
Trial: 23414298
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of calcipotriol ointment twice daily (group I)
Trial: 23414298
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy once a week (group II)
Trial: 23414298
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of heparinoid ointment twice daily and NB‐UVB phototherapy more than twice a week (group III)
Trial: 23414298
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy more than twice a week (group IV)
Trial: 21347647
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Tamoxifen (CTT)
Trial: 17015900
Drug: Contrast-enhanced full-dose
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced full-dose PET/CT
Trial: 17015900
Drug: Unenhanced low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Unenhanced low-dose PET/CT
Trial: 12643320
Drug: Danaparoid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danaparoid (10 IU/kg) administered subcutaneously twice daily for a mean of 16 days.
Trial: 12643320
Drug: Danaparoid (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danaparoid (2.6 IU/kg/h) administered intravenously for a mean of 17 days.
Trial: 30362518
Drug: Chemoradiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy plus enoxaparin (40 mg daily)
Trial: 28619985
Drug: Rhythm-and-music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm-and-music therapy
Trial: 28619985
Drug: Horse-riding therapy
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse-riding therapy
Trial: 28619985
Drug: Rhythm-and-music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm-and-music therapy and Horse-riding therapy
Trial: 19531521
Drug: Betamethasone (BM)
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone (BM) 12 mg
Trial: 17915499
Drug: Classroom-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom-administered cognitive enhancement program (COGENT) throughout the school year
Trial: 15518095
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg with dexamethasone 8 mg (group OD)
Trial: 3234635
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg three times daily for 3 days
Trial: 31496659
Drug: Tiopronin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin (15 mg/kg, 24 hrs)
Trial: 31496659
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (792 mg/kg, 24 hrs)
Trial: 28575389
Drug: Imipenem/cilastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin + 250 mg relebactam
Trial: 28575389
Drug: Imipenem/cilastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin + 125 mg relebactam
Trial: 28575389
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (treatment-emergent adverse events)
Trial: 21968856
Drug: Dietetic Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietetic Intervention Treatment (DIT)
Trial: 19489504
Drug: G 6805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G 6805 electronic stimulator
Trial: 17406651
Drug: Measurement-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement-based care (MBC) approach with citalopram as the first treatment step